Almirall, S.A. (ALM.MC)
EUR 8.31
(1.03%)
EUR 8.31
(1.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 911.58 Million EUR | 9.97% |
| 2022 | 828.97 Million EUR | -3.12% |
| 2021 | 855.7 Million EUR | -13.4% |
| 2020 | 988.14 Million EUR | -14.79% |
| 2019 | 1.15 Billion EUR | -3.19% |
| 2018 | 1.19 Billion EUR | 14.86% |
| 2017 | 1.04 Billion EUR | -19.68% |
| 2016 | 1.29 Billion EUR | 21.36% |
| 2015 | 1.06 Billion EUR | -10.92% |
| 2014 | 1.2 Billion EUR | 35.78% |
| 2013 | 884.38 Million EUR | 104.51% |
| 2012 | 432.44 Million EUR | -28.15% |
| 2011 | 601.89 Million EUR | -16.1% |
| 2010 | 717.4 Million EUR | -1.99% |
| 2009 | 732 Million EUR | -47.58% |
| 2008 | 1.39 Billion EUR | 61.35% |
| 2007 | 865.45 Million EUR | 146.6% |
| 2006 | 350.96 Million EUR | 15.5% |
| 2005 | 303.85 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 831 Million EUR | -8.18% |
| 2024 Q2 | 816.15 Million EUR | 0.46% |
| 2023 Q2 | 818.57 Million EUR | 1.84% |
| 2023 FY | 911.58 Million EUR | 9.97% |
| 2023 Q1 | 803.8 Million EUR | -3.04% |
| 2023 Q3 | 820.3 Million EUR | 0.21% |
| 2023 Q4 | 905 Million EUR | 10.33% |
| 2022 Q2 | 785.31 Million EUR | 0.0% |
| 2022 FY | 828.97 Million EUR | -3.12% |
| 2022 Q4 | 828.97 Million EUR | 0.0% |
| 2021 Q4 | 855.7 Million EUR | -21.23% |
| 2021 Q2 | 929.91 Million EUR | -5.74% |
| 2021 FY | 855.7 Million EUR | -13.4% |
| 2021 Q1 | 986.5 Million EUR | -0.17% |
| 2021 Q3 | 1.08 Billion EUR | 16.82% |
| 2020 Q1 | 1.03 Billion EUR | -10.5% |
| 2020 Q2 | 996.64 Million EUR | -3.98% |
| 2020 FY | 988.14 Million EUR | -14.79% |
| 2020 Q4 | 988.14 Million EUR | 2.28% |
| 2020 Q3 | 966.1 Million EUR | -3.06% |
| 2019 Q2 | 1.28 Billion EUR | 3.59% |
| 2019 FY | 1.15 Billion EUR | -3.19% |
| 2019 Q1 | 1.23 Billion EUR | 3.32% |
| 2019 Q3 | 1.21 Billion EUR | -4.9% |
| 2019 Q4 | 1.15 Billion EUR | -4.88% |
| 2018 FY | 1.19 Billion EUR | 14.86% |
| 2018 Q2 | 804.13 Million EUR | -6.28% |
| 2018 Q3 | 1.21 Billion EUR | 51.7% |
| 2018 Q1 | 858 Million EUR | -17.72% |
| 2018 Q4 | 1.19 Billion EUR | -1.82% |
| 2017 Q3 | 915.8 Million EUR | -7.11% |
| 2017 Q4 | 1.04 Billion EUR | 13.86% |
| 2017 Q2 | 985.88 Million EUR | -21.14% |
| 2017 Q1 | 1.25 Billion EUR | -3.7% |
| 2017 FY | 1.04 Billion EUR | -19.68% |
| 2016 Q1 | 1.2 Billion EUR | 12.69% |
| 2016 FY | 1.29 Billion EUR | 21.36% |
| 2016 Q3 | 1.26 Billion EUR | 9.79% |
| 2016 Q4 | 1.29 Billion EUR | 2.24% |
| 2016 Q2 | 1.15 Billion EUR | -4.06% |
| 2015 Q1 | 1.14 Billion EUR | -4.61% |
| 2015 Q3 | 1.09 Billion EUR | -1.34% |
| 2015 Q4 | 1.06 Billion EUR | -2.22% |
| 2015 FY | 1.06 Billion EUR | -10.92% |
| 2015 Q2 | 1.1 Billion EUR | -3.19% |
| 2014 Q4 | 1.2 Billion EUR | 38.92% |
| 2014 FY | 1.2 Billion EUR | 35.78% |
| 2014 Q2 | 892.02 Million EUR | 0.25% |
| 2014 Q1 | 889.8 Million EUR | 0.61% |
| 2014 Q3 | 864.4 Million EUR | -3.1% |
| 2013 Q2 | 392.49 Million EUR | -70.53% |
| 2013 Q3 | 395.7 Million EUR | 0.82% |
| 2013 Q4 | 884.38 Million EUR | 123.5% |
| 2013 FY | 884.38 Million EUR | 104.51% |
| 2013 Q1 | 1.33 Billion EUR | 207.95% |
| 2012 Q3 | 455.1 Million EUR | -6.75% |
| 2012 Q4 | 432.44 Million EUR | -4.98% |
| 2012 FY | 432.44 Million EUR | -28.15% |
| 2012 Q1 | 570.1 Million EUR | -5.28% |
| 2012 Q2 | 488.06 Million EUR | -14.39% |
| 2011 Q2 | 702.2 Million EUR | 3.6% |
| 2011 Q3 | 664.9 Million EUR | -5.31% |
| 2011 Q4 | 601.89 Million EUR | -9.48% |
| 2011 FY | 601.89 Million EUR | -16.1% |
| 2011 Q1 | 677.8 Million EUR | -5.52% |
| 2010 Q1 | 670.3 Million EUR | -8.43% |
| 2010 Q4 | 717.4 Million EUR | 5.08% |
| 2010 FY | 717.4 Million EUR | -1.99% |
| 2010 Q3 | 682.7 Million EUR | 1.34% |
| 2010 Q2 | 673.7 Million EUR | 0.51% |
| 2009 FY | 732 Million EUR | -47.58% |
| 2009 Q4 | 732 Million EUR | 0.0% |
| 2008 FY | 1.39 Billion EUR | 61.35% |
| 2007 FY | 865.45 Million EUR | 146.6% |
| 2006 FY | 350.96 Million EUR | 15.5% |
| 2005 FY | 303.85 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Faes Farma, S.A. | 112.68 Million EUR | -709.003% |
| Laboratorio Reig Jofre, S.A. | 124.61 Million EUR | -631.498% |